Resonium: Uses, Dosage & Side Effects
A cation exchange resin used to treat hyperkalemia (high potassium levels) by binding potassium in the gastrointestinal tract and promoting its removal from the body
Resonium (sodium polystyrene sulfonate) is a cation exchange resin used to treat hyperkalemia – a condition in which blood potassium levels are dangerously elevated. Hyperkalemia can cause serious and potentially life-threatening disturbances to heart rhythm. Resonium works by passing through the gastrointestinal tract and exchanging sodium ions for potassium ions, primarily in the large intestine. The potassium-loaded resin is then excreted in the feces, effectively lowering blood potassium levels. Resonium is not absorbed into the body. It is available as a powder that can be taken orally (mixed with water, juice, or soft food) or administered rectally as a retention enema. Regular blood tests are essential during treatment to monitor electrolyte balance and prevent over-correction of potassium levels.
Quick Facts: Resonium
Key Takeaways
- Resonium (sodium polystyrene sulfonate) is a potassium-binding resin used to treat hyperkalemia – dangerously elevated blood potassium levels that can cause life-threatening cardiac arrhythmias.
- The resin is not absorbed into the body; it works by exchanging sodium for potassium ions in the gastrointestinal tract, with the bound potassium then excreted in the feces.
- Resonium must never be used concurrently with sorbitol due to the risk of fatal intestinal necrosis; it should also be taken at least 3 hours apart from other oral medications to avoid reduced absorption.
- Regular blood monitoring of potassium, sodium, calcium, and magnesium is essential during treatment, as the resin can cause electrolyte imbalances beyond just lowering potassium.
- Each dose contains approximately 1.7 g of sodium (85% of the recommended daily maximum), making careful monitoring necessary for patients with heart failure, hypertension, or fluid retention.
What Is Resonium and What Is It Used For?
Resonium belongs to a class of medications known as cation exchange resins, sometimes also referred to as potassium binders. The active substance, sodium polystyrene sulfonate, is a synthetic resin consisting of a polystyrene backbone with sulfonate groups. These sulfonate groups carry sodium ions that are available for exchange with potassium ions as the resin passes through the gastrointestinal tract. Each gram of resin can exchange approximately 0.5 to 1 milliequivalent (mEq) of potassium in clinical practice, though the in vitro capacity is somewhat higher.
Potassium is an essential electrolyte that plays a critical role in muscle contraction, nerve conduction, and maintaining normal heart rhythm. Under healthy conditions, the kidneys regulate potassium balance by excreting excess potassium in the urine. However, when kidney function is impaired – as in chronic kidney disease (CKD), acute kidney injury, or end-stage renal disease – the body may be unable to excrete potassium adequately, leading to hyperkalemia. Other causes of hyperkalemia include certain medications (such as ACE inhibitors, angiotensin receptor blockers, potassium-sparing diuretics, and NSAIDs), adrenal insufficiency (Addison’s disease), metabolic acidosis, tissue damage (rhabdomyolysis, burns, trauma), and excessive dietary potassium intake.
Hyperkalemia is defined as a serum potassium concentration above 5.0–5.5 mmol/L, depending on the laboratory reference range. Mild hyperkalemia (5.5–6.0 mmol/L) may be asymptomatic but still requires treatment. Moderate to severe hyperkalemia (above 6.0 mmol/L) can cause dangerous cardiac arrhythmias, including ventricular fibrillation and cardiac arrest, as well as muscle weakness, fatigue, and paresthesias (tingling sensations). Severe hyperkalemia is a medical emergency that requires immediate intervention.
Resonium is primarily used in the following clinical settings:
- Chronic kidney disease: Patients with reduced kidney function who develop persistent or recurrent hyperkalemia despite dietary potassium restriction and optimization of other medications.
- Acute hyperkalemia: As an adjunctive measure to lower potassium levels, often used alongside more rapidly acting treatments such as intravenous calcium gluconate (for cardiac protection), insulin with glucose (to shift potassium intracellularly), and inhaled salbutamol.
- Dialysis patients: To manage potassium levels between dialysis sessions, particularly in patients who are prone to inter-dialytic hyperkalemia.
- Drug-induced hyperkalemia: In patients taking medications that raise potassium levels, when discontinuation of the offending drug is not feasible or insufficient to normalize potassium.
It is important to understand that Resonium has a relatively slow onset of action compared to other acute hyperkalemia treatments. When taken orally, the effect typically begins within 2 to 12 hours. When given rectally as a retention enema, the onset may be faster (30 to 60 minutes), but the magnitude of potassium reduction may be somewhat less predictable. For this reason, Resonium is generally not used as the sole treatment for acute, life-threatening hyperkalemia, but rather as part of a comprehensive management strategy.
Treatment with Resonium requires regular blood tests to check potassium levels, as well as sodium, calcium, and magnesium. The resin exchanges sodium for potassium, so blood sodium levels may rise while other cation levels may fall. It is crucial that potassium levels are not lowered too quickly or too far, as hypokalemia (low potassium) can also be dangerous and cause cardiac arrhythmias.
What Should You Know Before Taking Resonium?
Contraindications
There are specific situations in which Resonium must not be used. Understanding these absolute contraindications is essential for safe treatment.
- Hypersensitivity: Do not use Resonium if you are allergic to sodium polystyrene sulfonate or any of the other ingredients in the product (vanillin, saccharin).
- Serum potassium below 5 mmol/L: Resonium must not be used when blood potassium levels are already at or below the normal range, as further reduction could cause dangerous hypokalemia.
- Obstructive bowel disease: Patients with bowel obstruction, ileus, or structural abnormalities of the gastrointestinal tract that could impair transit of the resin should not receive Resonium.
- Neonates with reduced gut motility: Resonium should not be given orally to neonates, and should not be given by any route to neonates with impaired bowel function, due to the risk of intestinal necrosis.
Warnings and Precautions
Cases of intestinal necrosis (tissue death in the bowel), sometimes fatal, have been reported with sodium polystyrene sulfonate. This risk is increased when the resin is used concurrently with sorbitol. Seek immediate medical attention if you experience severe abdominal pain, rectal pain, bloating, severe constipation, nausea and vomiting, or black, bloody, or tarry stools.
Before and during treatment with Resonium, inform your doctor if any of the following apply to you:
- Hypertension (high blood pressure): Resonium contains a significant amount of sodium. Each dose (approximately 15 g) delivers about 1.7 g of sodium, which is 85% of the WHO-recommended maximum daily sodium intake for adults. This sodium load can raise blood pressure and worsen hypertension.
- Heart failure: The substantial sodium content can cause fluid retention and worsen heart failure symptoms, including edema (swelling), breathlessness, and weight gain. Close monitoring and potentially dose adjustment are required.
- Edema (fluid retention): Patients already experiencing peripheral edema or ascites should use Resonium with caution because the sodium exchange will increase overall body sodium load.
- Constipation: Resonium can cause or worsen constipation. If constipation develops during treatment, inform your doctor immediately. Prolonged transit time increases the risk of fecal impaction and intestinal complications. Sorbitol must not be used as a laxative to treat constipation caused by Resonium.
- Reduced bowel motility: Patients with abnormal gut motility (for example, following surgery, due to opioid use, or associated with certain neurological conditions) are at increased risk of gastrointestinal complications including bowel impaction, ischemia, and perforation.
- Electrolyte imbalances: In addition to lowering potassium, Resonium can affect calcium and magnesium levels. Hypocalcemia (low calcium) and hypomagnesemia (low magnesium) may occur and require supplementation.
Pregnancy and Breastfeeding
Resonium is not absorbed from the gastrointestinal tract, which theoretically limits the risk of systemic effects on the fetus or nursing infant. However, there is insufficient clinical data on the use of sodium polystyrene sulfonate during pregnancy and breastfeeding. The sodium load delivered by the resin could potentially contribute to fluid retention and hypertension in pregnant women, particularly those with pre-eclampsia or gestational hypertension.
If you are pregnant, think you may be pregnant, are planning to become pregnant, or are breastfeeding, consult your doctor before using Resonium. Your physician will carefully weigh the potential benefits of treating hyperkalemia against any possible risks to you and your baby.
Driving and Operating Machinery
Resonium has no known effect on the ability to drive or operate machinery. However, if you experience symptoms of electrolyte imbalance such as muscle weakness, confusion, or dizziness during treatment, you should refrain from driving or operating heavy equipment until these symptoms resolve.
Important Information About Sodium Content
Each dose of Resonium (approximately 15 g) contains about 1.7 g of sodium, equivalent to 85% of the WHO-recommended maximum daily sodium intake for adults. This is particularly important for patients on sodium-restricted diets, or those with heart failure, hypertension, or kidney disease. Discuss with your doctor if you need to take Resonium regularly over a prolonged period.
How Does Resonium Interact with Other Drugs?
Because Resonium acts as a non-selective cation exchanger in the gastrointestinal tract, it has the potential to interact with a wide range of other medications. The resin can bind to other drugs and reduce their absorption, and it can also exchange ions other than potassium, leading to complex electrolyte interactions. It is essential to inform your doctor about all medications, supplements, and herbal products you are taking.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Sorbitol | Risk of intestinal necrosis (tissue death in the bowel), potentially fatal | Absolute contraindication – never combine. Deaths have been reported. |
| Antacids (magnesium hydroxide, aluminum hydroxide) | Can reduce Resonium’s potassium-binding capacity; risk of metabolic alkalosis | Avoid concurrent use; separate by at least 3 hours |
| Digoxin | Resonium-induced hypokalemia and hypocalcemia increase risk of digoxin toxicity; resin may also bind digoxin | Monitor digoxin levels and electrolytes closely |
| Lithium | Resin may bind lithium and reduce its absorption, lowering therapeutic levels | Monitor lithium levels; dose adjustment may be required |
Minor Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Levothyroxine (thyroid hormones) | Resin may bind levothyroxine and reduce absorption | Separate doses by at least 3–6 hours; monitor thyroid function |
| Laxatives (non-sorbitol) | May accelerate gastrointestinal transit, reducing time for potassium exchange | Use with caution; may reduce Resonium effectiveness |
| Other oral medications (general) | Resonium can bind to and reduce absorption of many orally administered drugs | Take Resonium at least 3 hours before or after other oral medications (6 hours with gastroparesis) |
| ACE inhibitors / ARBs / Potassium-sparing diuretics | These drugs raise potassium; concurrent use with Resonium may be intentional but requires careful balance | Monitor potassium levels frequently; dose adjustments may be needed |
As a general rule, Resonium should not be taken at the same time as any other oral medication. A separation of at least 3 hours is recommended. For patients with delayed gastric emptying (gastroparesis), a 6-hour separation is advised. This is because the resin can non-specifically bind other medications in the gastrointestinal tract, reducing their absorption and potentially compromising their therapeutic effectiveness.
What Is the Correct Dosage of Resonium?
Resonium is always prescribed and dosed under medical supervision. Your doctor will determine the appropriate dose based on your blood potassium level, kidney function, and overall clinical condition. Regular blood tests are essential to guide dosing adjustments and ensure that potassium levels do not fall too low.
Adults
Oral Administration
Standard dose: 15 g (one level measuring scoop) taken 3 to 4 times daily
Preparation: Mix the powder in a small amount of water (not fruit juice containing potassium), or stir into soft food such as porridge, jam, or syrup. The suspension should be consumed immediately after preparation.
Important: Take care when mixing and ingesting the powder to avoid inhaling it. Aspiration (inhalation) of the powder can cause bronchitis or pneumonia.
Rectal Administration (Retention Enema)
Standard dose: 30 g suspended in 100–150 mL of a suitable vehicle (such as methylcellulose solution or water)
Administration: Given as a retention enema, which should be retained for the duration specified by your doctor (typically at least 6–9 hours) before being expelled
Notes: Rectal administration is used when oral administration is not possible. The rectum should be irrigated with a non-sodium solution after the enema is expelled.
Children
Pediatric Dosing
Dose: Individualized based on the child’s weight and potassium levels, under specialist supervision
Neonates: Resonium must not be given orally to neonates. Rectal use in neonates is only considered when oral administration is not feasible and requires extreme caution. Do not use in neonates with reduced gut motility.
Older children: A typical starting dose is 1 g/kg body weight per day, divided into multiple doses. Your doctor will adjust the dose based on potassium monitoring.
Elderly
No specific dose adjustment is required for elderly patients based on age alone. However, elderly patients are more likely to have reduced kidney function, heart failure, and constipation, all of which require careful consideration when prescribing Resonium. The sodium content is particularly relevant in elderly patients with cardiovascular disease. Close monitoring of electrolytes and bowel function is essential.
Missed Dose
If you miss a dose of Resonium, take it as soon as you remember, unless it is nearly time for your next scheduled dose. In that case, skip the missed dose and continue with your normal dosing schedule. Do not take a double dose to make up for a forgotten dose. If you are unsure, contact your doctor or pharmacist for advice.
Overdose
Overdose with Resonium can cause severe electrolyte disturbances, particularly hypokalemia (dangerously low potassium). Symptoms may include irritability, confusion, delayed thinking, muscle weakness, weakened reflexes, and in severe cases paralysis. Respiratory arrest is a possible serious consequence. If you suspect an overdose, seek emergency medical attention immediately.
In case of overdose, treatment is primarily supportive and focused on correcting the resulting electrolyte abnormalities. Intravenous potassium supplementation may be required under close cardiac monitoring. The resin should be removed from the gastrointestinal tract if possible, for example by gastric lavage or whole bowel irrigation if the ingestion was recent.
What Are the Side Effects of Resonium?
Like all medicines, Resonium can cause side effects, although not everybody gets them. Many of the side effects are related to the resin’s mechanism of action (ion exchange) and its physical properties (a large volume of powder that must be consumed). The most clinically significant risks involve the gastrointestinal tract and electrolyte balance.
Provided that electrolyte balance is maintained, the most frequently reported difficulties involve the practicality of consuming the relatively large amount of mixed powder. Patients often find it challenging to maintain adequate variation in the foods and drinks used for mixing, and some find the taste and texture unpleasant over time.
Common Side Effects
Affects more than 1 in 100 patients
- Constipation or fecal impaction
- Nausea and vomiting
- Loss of appetite (anorexia)
- Diarrhea
- Electrolyte disturbances (hypokalemia, hypomagnesemia, hypocalcemia, hypernatremia)
- Difficulty and unpleasantness when swallowing the preparation
Rare Side Effects
Affects fewer than 1 in 1,000 patients
- Bronchitis or pneumonia (often due to aspiration/inhalation of the powder)
- Intestinal obstruction (ileus)
- Intestinal ischemia (reduced blood supply to the bowel)
- Colitis (inflammation of the colon)
- Intestinal ulceration or necrosis (tissue death), sometimes fatal
Serious GI Events (Frequency Not Fully Established)
Reported in post-marketing surveillance
- Intestinal perforation (bowel rupture)
- Gastrointestinal bleeding
- Colonic necrosis (especially when used with sorbitol)
Contact your doctor or seek emergency care immediately if you experience any of the following symptoms: severe abdominal pain, rectal pain or bleeding, severe bloating, severe constipation, intense nausea and vomiting, or black, bloody, or tarry stools. These may indicate serious gastrointestinal complications that require urgent treatment.
Electrolyte disturbances are among the most clinically important side effects. Because Resonium exchanges sodium for potassium non-selectively, it can also exchange sodium for other cations including calcium and magnesium. This can lead to hypokalemia, hypocalcemia, and hypomagnesemia, all of which can cause their own clinical problems. Regular blood tests are therefore mandatory during treatment. Your doctor will supplement these electrolytes if necessary.
The sodium load delivered by the resin can lead to hypernatremia (high sodium levels) and fluid retention, which may manifest as peripheral edema, weight gain, or worsening of heart failure symptoms. Patients on sodium-restricted diets or with pre-existing cardiovascular conditions are particularly vulnerable to these effects.
If you experience any side effects, including those not listed here, inform your doctor or pharmacist. Reporting suspected adverse reactions helps regulatory authorities to continuously monitor the benefit-risk balance of the medicine.
How Should You Store Resonium?
Proper storage of Resonium is important to maintain the effectiveness and safety of the product. Follow these guidelines:
- Temperature: Store at or below 25°C (77°F). Do not refrigerate or freeze.
- Container: Keep in the original container with the lid tightly closed. The powder is sensitive to moisture and should be protected from humidity.
- Prepared suspension: If Resonium powder is mixed with water, the resulting suspension must be used within 24 hours. Heating should be avoided as it may affect the resin’s exchange capacity.
- Expiry date: Do not use after the expiration date printed on the label (marked “EXP”). The expiration date refers to the last day of the indicated month.
- Children: Keep out of sight and reach of children.
- Disposal: Do not dispose of medicines via wastewater or household waste. Return unused or expired medicines to your pharmacist for safe disposal to protect the environment.
What Does Resonium Contain?
Active Ingredient
The active substance is sodium polystyrene sulfonate. Each 100 g of powder contains 99.934 g of sodium polystyrene sulfonate. This means the product is nearly pure active ingredient, with only trace amounts of excipients. Sodium polystyrene sulfonate is a synthetic cation exchange resin with a polystyrene backbone bearing sulfonate functional groups loaded with sodium ions.
Inactive Ingredients (Excipients)
- Vanillin: Used as a flavoring agent to improve the taste of the preparation
- Saccharin: Used as an artificial sweetener to make the preparation more palatable
Appearance and Packaging
Resonium is a light brown powder supplied in a plastic container holding 450 g of powder for oral or rectal suspension. A measuring scoop is included in the package; one level scoop holds approximately 15 g of powder. The powder should be mixed with water or incorporated into suitable food before administration.
Manufacturer
Resonium is manufactured by Sanofi Winthrop Industrie, Amilly, France. The marketing authorization is held by Sanofi. Resonium and its equivalents (Kayexalate, Kionex) are available in many countries worldwide.
Frequently Asked Questions About Resonium
Resonium (sodium polystyrene sulfonate) is used to treat hyperkalemia – a condition where the level of potassium in the blood is dangerously high. Elevated potassium can cause serious heart rhythm disturbances and can be life-threatening. Resonium is most commonly prescribed for patients with kidney disease, those on dialysis, or patients taking medications that raise potassium levels. It works by binding potassium in the gastrointestinal tract and replacing it with sodium, with the potassium-loaded resin then being excreted in the feces.
The onset of action depends on the route of administration. When taken orally, Resonium typically begins to lower potassium levels within 2 to 12 hours. When given rectally as a retention enema, the effect may begin within 30 to 60 minutes, though the degree of potassium lowering may be somewhat variable. Because of this relatively slow onset, Resonium is not used as the sole treatment for acute, life-threatening hyperkalemia, but is often combined with faster-acting interventions such as insulin with glucose or intravenous calcium gluconate.
Yes, in fact Resonium powder is intended to be mixed with food or liquid before ingestion. It can be stirred into a small amount of water, or mixed into soft foods such as porridge, syrup, or jam. Avoid mixing with fruit juices high in potassium (such as orange juice) as this would partially counteract the purpose of the medication. The key requirement is that the powder is fully suspended and consumed promptly after mixing. Care should be taken to avoid inhaling the dry powder during preparation.
The combination of sodium polystyrene sulfonate and sorbitol has been associated with severe gastrointestinal adverse events, including intestinal necrosis (tissue death in the bowel), which can be fatal. Multiple deaths have been reported when sorbitol was used as a laxative alongside sodium polystyrene sulfonate. The exact mechanism is not fully understood, but it is believed that sorbitol may cause direct mucosal damage that is exacerbated by the presence of the resin. For this reason, concurrent use of Resonium with sorbitol is absolutely contraindicated. Note that this warning refers to sorbitol used as a laxative; there is limited information about sorbitol used as a sweetener in other medications or food products.
Yes, newer potassium binders have been developed as alternatives to sodium polystyrene sulfonate. Patiromer (Veltassa) and sodium zirconium cyclosilicate (Lokelma) are two more recently approved agents that have demonstrated efficacy in lowering potassium with potentially improved gastrointestinal tolerability and a lower risk of intestinal necrosis compared with sodium polystyrene sulfonate. However, these newer agents are generally more expensive, and sodium polystyrene sulfonate (Resonium) remains widely used and effective when used appropriately with proper monitoring. Your doctor will determine which potassium binder is most suitable for your individual situation.
In clinical practice, each gram of sodium polystyrene sulfonate can bind approximately 0.5 to 1 milliequivalent (mEq) of potassium, although the in vitro exchange capacity is higher (approximately 3.1 mEq/g). The actual amount removed depends on several factors including gastrointestinal transit time, the potassium concentration in the gut, and the route of administration. A typical daily oral dose of 60 g (15 g four times daily) might be expected to remove approximately 30 to 60 mEq of potassium. Your doctor will monitor your blood potassium levels to assess the actual effect and adjust the dose accordingly.
References
- European Medicines Agency (EMA). Resonium (sodium polystyrene sulfonate) – Summary of Product Characteristics. Last updated 2023. Available from: EMA.
- Sterns RH, Grieff M, Bernstein PL. Treatment of hyperkalemia: Something old, something new. Kidney Int. 2016;89(3):546–554. doi:10.1016/j.kint.2015.11.018.
- Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2024.
- Harel Z, Harel S, Shah PS, et al. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: A systematic review. Am J Med. 2013;126(3):264.e9–264.e24. doi:10.1016/j.amjmed.2012.08.016.
- Lepage L, Dufour AC, Doiron J, et al. Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD. Clin J Am Soc Nephrol. 2015;10(12):2136–2142. doi:10.2215/CJN.03640415.
- Kovesdy CP. Updates in hyperkalemia: Outcomes and therapeutic strategies. Rev Endocr Metab Disord. 2017;18(1):41–47. doi:10.1007/s11154-016-9384-x.
- British National Formulary (BNF). Sodium polystyrene sulfonate. Updated 2025. Available from: BNF Online.
- Palmer BF, Carrero JJ, Clegg DJ, et al. Clinical Management of Hyperkalemia. Mayo Clin Proc. 2021;96(3):744–762. doi:10.1016/j.mayocp.2020.06.014.
- UK Renal Association. Emergency Management of Hyperkalemia in Adults. Clinical Practice Guideline. 2023.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in nephrology, internal medicine, and clinical pharmacology.
Medical Content
iMedic Nephrology Editorial Team – specialist physicians in renal medicine with clinical experience in electrolyte disorders and hyperkalemia management
Medical Review
iMedic Medical Review Board – independent panel verifying accuracy against EMA SmPC, BNF, KDIGO, and UK Renal Association guidelines
Pharmacology Review
iMedic Clinical Pharmacology Team – specialists in drug interactions, pharmacokinetics, and medication safety
Accessibility & SEO
iMedic Digital Health Team – ensuring WCAG 2.2 AAA compliance and optimal search visibility
All content follows the GRADE evidence framework and is reviewed according to international medical guidelines. iMedic receives no commercial funding from pharmaceutical companies.